Understanding the factors that lead to the therapeutic success of adoptive cell therapies using tumor-infiltrating lymphocytes (TIL-ACT) will improve current treatment protocols. In this issue of Immunity, Chiffelle et al. comprehensively compare the dynamics of CD8 T cell clonotypes during the course of ACT between responding and non-responding patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.immuni.2024.09.012 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!